thrombophilia sometimes called hypercoagulability prothrombotic state abnormality blood coagulation increases risk thrombosis blood clots blood abnormalities identified people episode thrombosis deep vein thrombosis leg provoked significant proportion population detectable thrombophilic abnormality develop thrombosis presence additional risk specific treatment thrombophilias recurrent episodes thrombosis may indication longterm preventive first major form thrombophilia identified medical science antithrombin deficiency identified common abnormalities including factor v leiden described common conditions associated thrombophilia deep vein thrombosis dvt pulmonary embolism pe referred collectively venous thromboembolism vte dvt usually occurs legs characterized pain swelling redness limb may lead longterm swelling heaviness due damage valves clot may also break migrate embolize arteries lungs depending size location clot may lead suddenonset shortness breath chest pain palpitations may complicated collapse shock cardiac venous thrombosis may also occur unusual places veins brain liver portal vein thrombosis hepatic vein thrombosis mesenteric vein kidney renal vein thrombosis veins whether thrombophilia also increases risk arterial thrombosis underlying cause heart attacks strokes less well however recent data suggest forms inherited thrombophilia associated increased risk arterial ischemic thrombophilia linked recurrent possibly various complications pregnancy intrauterine growth restriction stillbirth severe preeclampsia abruptio protein c deficiency may cause purpura fulminans severe clotting disorder newborn leads tissue death bleeding skin organs condition also described adults protein c protein deficiency also associated increased risk skin necrosis commencing anticoagulant treatment warfarin related thrombophilia congenital acquired congenital thrombophilia refers inborn conditions usually hereditary case hereditary thrombophilia may used increase tendency develop thrombosis hand acquired thrombophilia refers conditions arise later life common types congenital thrombophilia arise result overactivity coagulation factors relatively mild therefore classified type ii common ones factor v leiden mutation gene position prothrombin mutation prothrombin position untranslated region rare forms congenital thrombophilia typically caused deficiency natural anticoagulants classified type severe propensity cause main ones antithrombin iii deficiency protein c deficiency protein milder rare congenital thrombophilias factor xiii familial dysfibrinogenemia abnormal unclear whether congenital disorders fibrinolysis system destroys clots major contributors thrombosis congenital deficiency plasminogen instance mainly causes eye symptoms sometimes problems organs link thrombosis blood group determines thrombosis risk significant extent blood groups type relative risk blood group associated reduced levels von willebrand factor increased clearance factor viii related thrombotic risk number acquired conditions augment risk thrombosis prominent example antiphospholipid caused antibodies constituents cell membrane particularly lupus anticoagulant first found people disease systemic lupus erythematosus often detected people without disease anticardiolipin antibodies antibodies therefore regarded autoimmune disease cases antiphospholipid syndrome cause arterial well venous thrombosis also strongly associated miscarriage cause number symptoms livedo reticularis skin heparininduced thrombocytopenia hit due immune system reaction anticoagulant drug heparin though named associated low platelet counts hit strongly associated risk venous arterial paroxysmal nocturnal hemoglobinuria pnh rare condition resulting acquired alterations piga gene plays role protection blood cells complement system pnh increases risk venous thrombosis also associated hemolytic anemia anemia resulting destruction red blood hit pnh require particular hematologic conditions associated sluggish blood flow increase risk thrombosis example sicklecell disease caused mutations hemoglobin regarded mild prothrombotic state induced impaired similarly myeloproliferative disorders bone marrow produces many blood cells predispose thrombosis particularly polycythemia vera excess red blood cells essential thrombocytosis excess platelets conditions usually warrant specific treatment cancer particularly metastatic spread places body recognised risk factor number mechanisms proposed activation coagulation system cancer cells secretion procoagulant substances furthermore particular cancer treatments use central venous catheters chemotherapy may increase risk thrombosis nephrotic syndrome protein bloodstream released urine due kidney diseases predispose particularly case severe cases indicated blood levels albumin gl syndrome caused condition membranous inflammatory bowel disease ulcerative colitis crohns disease predispose thrombosis particularly disease active various mechanisms pregnancy associated increased risk thrombosis probably results physiological hypercoagulability pregnancy protects postpartum hypercoagulability turn likely related high levels estradiol progesterone occur estrogens used combined hormonal birth control menopausal hormone therapy combination progestogens associated increased risk venous thrombosis risk depends types hormones used dose estrogen presence thrombophilic risk various mechanisms deficiency protein tissue factor pathway inhibitor said obesity long regarded risk factor venous thrombosis doubles risk numerous studies particularly combination use oral contraceptives period surgery various coagulation abnormalities described obese plasminogen activator inhibitor fibrinolysis present higher levels people obesity obese people also larger numbers circulating microvesicles fragments damaged cells bear tissue factor platelet aggregation may increased higher levels coagulation proteins von willebrand factor fibrinogen factor vii factor viii obesity also increases risk recurrence initial episode number conditions linked venous thrombosis possibly genetic possibly include elevated levels factor viii factor ix factor xi fibrinogen thrombinactivatable fibrinolysis inhibitor decreased levels tissue factor pathway inhibitor activated protein c resistance attributable factor v mutations probably caused factors remains risk factor association blood levels homocysteine although reported consistently homocysteine levels determined mutations mthfr cbs genes also levels folic acid vitamin vitamin depend thrombosis multifactorial problem often multiple reasons person might develop thrombosis risk factors may include combination abnormalities blood vessel wall abnormalities blood flow immobilization abnormalities consistency blood thrombophilia caused abnormalities blood consistency determined levels coagulation factors circulating blood proteins participate coagulation normal coagulation initiated release tissue factor damaged tissue tissue factor binds circulating factor viia combination activates factor x factor xa factor ix factor ixa factor xa presence factor v activates prothrombin thrombin thrombin central enzyme coagulation process generates fibrin fibrinogen activates number enzymes cofactors factor xiii factor xi factor v factor viii tafi enhance fibrin process inhibited tfpi inactivates first step catalyzed factor viiatissue factor antithrombin inactivates thrombin factor ixa xa xia protein c inhibits factors va viiia presence protein protein z inhibits factor thrombophilia balance procoagulant anticoagulant activity disturbed severity imbalance determines likelihood someone develops thrombosis even small perturbances proteins reduction antithrombin normal level increase thrombosis risk contrast hemophilia arises levels coagulation factors markedly addition effects thrombosis hypercoagulable states may accelerate development atherosclerosis arterial disease underlies myocardial infarction forms cardiovascular tests thrombophilia include complete blood count examination blood film prothrombin time partial thromboplastin time thrombodynamics test thrombin time reptilase time lupus anticoagulant anticardiolipin antibody glycoprotein antibody activated protein c resistance fibrinogen tests factor v leiden prothrombin mutation basal homocysteine testing may less extensive depending clinical judgement abnormalities detected initial hereditary cases patient must least two abnormal tests plus family history divergent views whether everyone unprovoked episode thrombosis investigated thrombophilia even form thrombophilia may necessarily risk thrombosis recurrent thrombosis likely previous thrombosis even detectable thrombophilic recurrent thromboembolism thrombosis unusual sites eg hepatic vein buddchiari syndrome generally accepted indication screening likely costeffective people strong personal family history contrast combination thrombophilia risk factors may provide indication preventive treatment thrombophilia testing may performed even would meet strict criteria searching coagulation abnormality normally undertaken patients thrombosis obvious trigger example thrombosis due immobilization recent orthopedic surgery regarded provoked immobilization surgery less likely investigations yield clinically important venous thromboembolism occurs patient experiencing transient major risk factors prolonged immobility surgery trauma testing thrombophilia appropriate outcome test would change patients indicated american society hematology part recommendations choosing wisely campaign cautioned overuse thrombophilia screening false positive results testing would lead people inappropriately labeled thrombophilia treated anticoagulants without clinical united kingdom professional guidelines give specific indications thrombophilia testing recommended testing done appropriate counseling hence investigations usually performed time thrombosis diagnosed later particular situations retinal vein thrombosis testing discouraged altogether thrombophilia regarded major risk factor rare conditions generally linked hypercoagulability cerebral venous thrombosis portal vein thrombosis insufficient data state certain whether thrombophilia screening helpful decisions thrombophilia screening conditions therefore regarded costeffectiveness qualityadjusted life years return expenditure taken guide generally unclear whether thrombophilia investigations justify often high unless testing restricted selected recurrent miscarriage indication thrombophilia screening particularly antiphospholipid antibodies anticardiolipin igg igm well lupus anticoagulant factor v leiden prothrombin mutation activated protein c resistance general assessment coagulation investigation known women planning use oral contraceptives benefit routine screening thrombophilias absolute risk thrombotic events low either woman firstdegree relative thrombosis risk developing thrombosis increased screening selected group may even negative may still indicate residual professional guidelines therefore suggest alternative forms contraception used rather relying thrombophilia screening people arterial thrombosis generally regarded unrewarding generally except possibly unusually young patients especially precipitated smoking use estrogencontaining hormonal contraceptives revascularization coronary arterial bypass fails rapid occlusion specific treatment thrombophilia unless caused underlying medical illness nephrotic syndrome treatment underlying disease needed unprovoked andor recurrent thrombosis highrisk form thrombophilia important decision whether use anticoagulation medications warfarin longterm basis reduce risk risk needs weighed risk treatment cause significant bleeding reported risk major bleeding per year major bleeding may die apart abovementioned forms thrombophilia risk recurrence episode thrombosis determined factors extent severity original thrombosis whether provoked immobilization pregnancy number previous thrombotic events male sex presence inferior vena cava filter presence cancer symptoms postthrombotic syndrome factors tend important decision presence absence detectable antiphospholipid syndrome may offered longterm anticoagulation first unprovoked episode thrombosis risk determined subtype antibody detected antibody titer amount antibodies whether multiple antibodies detected whether detected repeatedly single women thrombophilia contemplating pregnancy pregnant usually require alternatives warfarin pregnancy especially first weeks may produce abnormalities unborn child low molecular weight heparin lmwh enoxaparin generally used warfarin lmwh may safely used women experience recurrent pregnancy loss secondary thrombophilia studies suggested low molecular weight heparin reduces risk miscarriage results studies analysed together statistically significant benefit could people without detectable thrombophilia cumulative risk developing thrombosis age people deficient antithrombin experienced thrombosis least age people protein c deficiency third protein deficiency people activated protein c resistance usually resulting factor v leiden contrast slightly raised absolute risk thrombosis least one thrombotic event age general men likely women experience repeated episodes venous people factor v leiden relatively low risk thrombosis may develop thrombosis presence additional risk factor immobilization people prothrombin mutation never develop major type thrombophilias rare antithrombin deficiency present general population people venous thrombosis protein c deficiency present population found people thrombosis exact prevalence protein deficiency population unknown found people minor type thrombophilias much common factor v leiden present population northern european descent much rarer asian african extraction people thrombosis factor v leiden referred thrombophilia testing defect prothrombin mutation occurs rates general population people thrombosis people referred thrombophilia testing like factor v leiden abnormality uncommon africans exact prevalence antiphospholipid syndrome well known different studies employ different definitions condition antiphospholipid antibodies detected referred thrombophilia german physician rudolf virchow categorized abnormalities consistency blood factor development thrombosis exact nature abnormalities remained elusive first form thrombophilia antithrombin deficiency recognized norwegian hematologist olav protein c deficiency followed described researchers scripps research institute us centers disease protein deficiency followed described researchers university antiphospholipid syndrome described full various previous reports specific antibodies people systemic lupus erythematosus syndrome often attributed british rheumatologist graham rv hughes often referred hughes syndrome common genetic thrombophilias described many studies previously indicated many people thrombosis showed resistance activated protein c group leiden netherlands identified common underlying mutation factor v made resistant action activated protein c defect called factor v leiden genetic abnormalities typically named place two years later group described common mutation prothrombin gene caused elevation prothrombin levels mild increase thrombosis suspected genetic abnormalities underlying familial thrombosis future discovered studies entire genetic code looking small alternations httpsenwikipediaorgwikithrombophilia